Protocol (b): J2W-MC-PYAA
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending 
Dose, Phase [ADDRESS_1077988] in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics 
and Pharmacodynamics of Intravenous LY3819253 in Participants Hospi[INVESTIGATOR_190290]-19
[STUDY_ID_REMOVED]   
Approval Date: 09-Jun-2020
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_77109]3819253 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries. 
Note to Regulatory Authorities:   This document may contain protected personal data and/or commercially confiden tial 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release.  In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may n ot be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title: A Rando mized, Placebo -Controlled, Double-Blind, Sponsor Unblinded, Single 
Ascending Dose, Phase [ADDRESS_1077989] in Human Study  toEvaluate the Safet y, 
Tolerabilit y,Pharmacokinet ics and Pharm acodynamics of Intravenous 
LY3819253 in Participants Hospi[INVESTIGATOR_80529] C OVID -19
Protocol Number: J2W- MC-PYAA
Amendment Number: (
b)
Compound :LY3819253
Study Phase: 1
Short Title: A rando mized, placebo -controlled, Phase 1 study  to eval uate LY3819253 in 
participants hospi [INVESTIGATOR_783847] -19
Sponsor Name: [CONTACT_32868]: Indianapo lis, Indiana [LOCATION_003] [ZIP_CODE]
Regulatory Agency Identifier Number(s)
IND: 150440
Approval Date:
Protocol  Electroni cally Si gned and Approved by [CONTACT_783880] 09 May  2020
Protocol Amendment (a) Electroni cally Signed and Approved by [CONTACT_229490]01 June 2020.
Protocol  Amendment (b) Electronically  Signed and Approved by  [CONTACT_141693].
Approval Date: 09-Jun-2020 GMT
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
2Medical Monitor Name [CONTACT_9352] [CONTACT_17055] .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Approval Date
Original Protocol 09 May  2020
Amendment (a) 01 June 2020
Amendment (b)
Overall Rationale for the Amendment:
This amendment addresses the [LOCATION_002] Food and Drug Administration ( FDA )feedback and 
clinical site feedback .   
Section # and Name [CONTACT_23688]
1.1 Synopsis Added text for Cohort 4 
randomizationProviding information for all 4 cohorts.
1.3Schedule of 
ActivitiesAdded clarification to laboratory 
tests and sample collection that 
documentation of hospi[INVESTIGATOR_307] -based 
laborato ry results are acceptableClarification for sites that hospi[INVESTIGATOR_783848].  
1.3 Schedule of 
ActivitiesUpdated comment for the SARS -
Cov-2 viral infection 
determinationExpanded the time of initial positive determination 
to 14 days prior to randomization
1.3 Schedule of 
ActivitiesPharmacodynamic sample 
instructio ns updated to include 
mid-turbinate methodPer site feedback
4.2. Scientific Rationale 
for Study DesignAdded text for Cohort 4 Per FDA f eedback.  Clarification as to why the 
study may expand to include the optional Cohort 
4.
5.1. Inclusion Criteria Updated Criterion #4 Changed 72 hours to 14 days per site feedback.
5.2. Exclusion Criteria Updated Criterion #21 Further clarification on timing of measurement
5.2. Exclusion Criteria Updated Criterion #24 Clarification that chronic kidney disease is 
allowed based on the opi[INVESTIGATOR_871], 
but acute kidney disease is not allowed.
8.6. Pharmacodynamics Added text to allow mid -
turbinate swab method.  Per site feedback
9.5. Interim Analyses Added text for Cohort 4 and 
further clarification on safety 
monitoringIn response to FDA feedback.
10.2. Appendix 2 Rem oved nasopharyngeal 
specific text for the 
pharmacodynam ic sampleNasophary ngeal or mid -turbinate swabs are now 
allowed
10.8. Appendix 8 Updated the contents to only 
contain the baseline severity 
categorizationFor ease of use.
Throughout the 
protocolMinor editorial and formatting 
changesMinor, therefore not described
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
4Table of Contents
1. Protocol Summary ...................................................................................................... [ADDRESS_1077990] ivities (SoA) ...................................................................................... 11
2. Introduction .............................................................................................................. 17
2.1. Study  Rati onale .......................................................................................................... 17
2.2. Background ................................................................................................................ 17
2.3. Benefit/Risk Assessment ............................................................................................ [ADDRESS_1077991] yle Considerat ions............................................................................................. 25
5.4. Screen Failures ........................................................................................................... 25
6. Study Intervention .................................................................................................... 26
6.1. Study  Intervent ion(s) Administered ............................................................................ 26
6.1.1. Speci al Treatm ent Consi derat ions............................................................................... 27
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 29
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 29
6.4. Study  Intervent ion Compliance ................................................................................... 30
6.5. Concomitant Therapy .................................................................................................30
6.6. Dose Modificat ion...................................................................................................... 31
6.6.1. Dose Escal ation Cri teria ............................................................................................. 31
6.6.2. Temporary  Stopp ing Criteria ...................................................................................... 31
6.7. Intervention after the End of the Study ........................................................................ 32
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 33
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 33
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. [ADDRESS_1077992] to Follow up ....................................................................................................... 34
8. Study Assessments and Procedures ......................................................................... 35
8.1. Efficacy Assessments .................................................................................................35
8.2. Safety Assessments .................................................................................................... 35
8.2.1. Physical Examinat ions................................................................................................ 35
8.2.2. Vital Signs.................................................................................................................. 35
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
58.2.3. Electro cardiograms ..................................................................................................... [ADDRESS_1077993] Complaint s.................................................................................................... 39
8.4. Treatment of Overdose ............................................................................................... 40
8.5. Pharmacokinet ics........................................................................................................ 40
8.5.1. Bioanaly tical.............................................................................................................. 40
8.6. Pharmacodynamics ..................................................................................................... 41
8.7. Genet ics..................................................................................................................... 41
8.8. Biomarkers ................................................................................................................. 41
8.9. Immunogenicit y.......................................................................................................... 41
8.10. Health Economics ....................................................................................................... 42
9. Statistical Considerations ......................................................................................... 43
9.1. Statistical Hypotheses .................................................................................................43
9.2. Sample Si ze Determinat ion......................................................................................... 43
9.3. Popul ations for Analyses ............................................................................................ 43
9.4. Statistical Analyses ..................................................................................................... 44
9.4.1. General Considerations ............................................................................................... 44
9.4.2. Safety Analyses .......................................................................................................... 44
9.4.3. Pharmacokinet ic and Pharmacodynamic Analyses ...................................................... 45
9.4.4. Exploratory  Endpo ints................................................................................................ 45
9.4.5. Immunogenicit y.......................................................................................................... 46
9.5. Interim Analyses ......................................................................................................... 46
9.6. Data Monitoring Committee (DMC) ........................................................................... 46
10. Supporting Documentation and Operational Considerations ................................ 47
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Conside rations
............................................................................................................ 47
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 47
10.1.2. Financial Disclo sure................................................................................................... 47
10.1.3. Inform ed Consent Process .......................................................................................... 47
10.1.4. Data Protection ........................................................................................................... 48
10.1.5. Committees Structure .................................................................................................48
10.1.6. Disseminat ion of Clinical Study  Data ......................................................................... 49
10.1.7. Data Qualit y Assurance .............................................................................................. 49
10.1.8. Source Documents ...................................................................................................... 50
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
610.1.9. Study  and Si te Start and Cl osure ................................................................................. [ADDRESS_1077994] igator Informat ion............................................................................................. 51
10.1.12. Long -Term  Sample Retent ion..................................................................................... 52
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 53
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 56
10.3.1. Definit ion of AE......................................................................................................... 56
10.3.2. Definit ion of SAE ....................................................................................................... 57
10.3.3. Recording and Fo llow-Up of AE and/or SAE ............................................................. 58
10.3.4. Reporting of SAEs ...................................................................................................... 60
10.4. Appendix 4: Contraceptive Guidance and Collect ion of 
Pregnancy Information ............................................................................................... 61
10.5. Appendix 5: Genetics .................................................................................................65
10.6. Appendix 6: Reco mmended Laboratory Test ing for 
Hypersensi tivity Events. ............................................................................................. 66
10.7. Appendix 7:  Nasopharyngeal Swab Instructions ........................................................ 68
10.8. Appendix 8: FDA Guidance for Industry  -Baseline Severit y 
Categorization for COVID -19..................................................................................... 69
10.9. Appendix 9: Abbreviat ions and Definit ions................................................................ 71
10.10. Protocol  Amendm ent Hi story ..................................................................................... 73
11. References ................................................................................................................. 77
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
71. Protocol Summary
1.1. Synopsis
Protocol Title :A Rando mized, Placebo -Controlled, Double-Blind, Sponsor Unblinded, Single 
Ascending Dose, Phase [ADDRESS_1077995] in Human Study  to Evaluate the Safet y, Tolerabili ty,
Pharmacokinet ics and Pharm acodynamics of Intravenous LY3819253 in Participants 
Hospi[INVESTIGATOR_80529] C OVID -19
Rationale :
The severe acute respi[INVESTIGATOR_447822] 2 ( SARS -CoV -2) has resulted in the 
pandemic spread of coronavi rus disease 2019 (COVID -
19), which in criticalcases results in 
progressive pulmo nary failure , com plicati ons wi th acute respi [INVESTIGATOR_41333] (ARDS) ,
and can result in death.  There is an urgent need for effect ive therapeutics to modify disease 
outcom es.
LY3819253 is a neutralizing IgG1 monoclonal antibod y(mAb) to the spi[INVESTIGATOR_119901] -
CoV -
2.  It is designed toblock viral attachment and entry into human cells ,and to neutraliz ethe
virus , potenti ally treating even established COVID -19 by  [CONTACT_4136] a specific potent, 
neutralizing ant ibodytoSARS -CoV -
2.
Study  J2W-MC-PYAA (PYAA) aims to invest igate the safet y, tolerabilit y, pharmacokinet ics 
(PK), and pharmacodynamics (PD) of LY3819253 following a single dose ofLY3819253
administered to participants hospi [INVESTIGATOR_191544] -19.
Objectives and Endpoint s:
Objectives Endpoints
Primary
Characterize the safety and tolerability of 
LY3819253 after intravenous infusion Safety assessments such as adverse event s 
and serious adverse events
Secondary
Characterize the pharmacokinetics of 
LY3819253 after intravenous infusionLY3819253 mean concentration on Day 29
Characterize the pharmacodynamics of 
LY3819253 after intravenous infusionChange f rom baseline in SARS -CoV -2 viral 
load (Day s 7, 11, 15 and 22)
SARS -CoV -2 viral load AUC
Time to SARS -CoV -2 clearance
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
8Overall Design :
Study  PYAA is a Phase 1, double -blind, sponsor unblinded, rando mized, placebo -controlled, 
single ascending dose study  in participants hospi[INVESTIGATOR_783849] d-19. 
Double -blind Treatment and Assessment Period
This is the general sequence of events during the treatment and assessment period :
Participants are randomized to LY3819253 or placebo
Site completes baseline procedures and sample collect ion
Parti cipants begin a single IV infusio nof study  intervent ion, and
Site completes all safety monitoring and post-infusio nsample co llection
.
Discharge from hospi[INVESTIGATOR_783850] … Then…
Occurs prior to Day 29 participants will be asked to complete the remaining 
study assessments at the timepoints indicated in the 
SoA.  
NOTE: Strategies to manage infection risks and reduce 
the burden of return visits should be consider ed by 
[CONTACT_21127], such as home visits .
Occurs on the same day as a study assessment visit hospi[INVESTIGATOR_783851] [ADDRESS_1077996] ion risksand reduce the burden of r eturn visits should be considered by [CONTACT_21127], such as ho me 
visits.
Disclosure Statement : This is a first in human, s equent ial, single ascending dose study  with up 
to [ADDRESS_1077997] igator blinded
.
Number of Participant s:
Cohorts 1 –3:  Approximately 24total participants .
Optional Cohort 4:  up to 100 total participants. 
Intervention Groups and Duration :Single -Ascending Dose Design
The study  will com prise up to [ADDRESS_1077998] 8 participants: 
6 randomized to LY3819253 and 
2 randomized to placebo.  
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
9Sentinel dosing will be utilized in any dose cohort that represents a dose increase fro m the 
preceding cohort.  When sent inel dosing, t he first 2 participants in each co hort will be 
rando mized 1:[ADDRESS_1077999] 4 day s after the IV infusio n by [CONTACT_1275] (s), Lilly sponsor team , and an independent safet y assessment committee (ISAC) .
The invest igator , Lilly sponsor team and ISAC areresponsible for determining any dose 
decisio ns.  The invest igator(s) will remain blinded and the Lilly sponsor team and ISAC will be 
unblinded during these reviews.  Allavailable data from previous cohorts will be reviewed .  
Available PK and PD (viro logy)data m ay also be used to gui de dose adjust ment. 
If tem porary  stoppi[INVESTIGATOR_783852] m et, dosing will be temporarily  stopped, and no further 
participants will be dosed unt il a full safet y review of the study  has taken pl ace.  TheISAC will 
be engaged for the full safety review wi th the sponsor and invest igator.  
For the opti onal Cohort 4, up to 100 participants may be rando mized in an approximate 1:1 ratio 
to receive either LY3819253 or placebo.  
Data Monitoring Committee: No
This study  will not have a data m onitoring commi ttee.  There will be a n ISAC .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
101.2. Schema
Abbreviations:  LY = Lilly study intervention
Figure 1. Sequential single ascending dose s chema of study J2W- MC-PYAACohort 1 –dose level 1Cohort 2 –dose level 2
= Sentinel subjects (1L Y, 1placebo)
= 4-day evaluation of all safety data in each cohort before next cohort and dose escalation
= Remainder of 29-day assessment period= Remaining participants are randomized and receive LY or placebo in the cohortCohort 3 –dose level 3Cohort 4 –optional –dose level will not exceed dose level 3
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
111.3. Schedule of Activities (SoA)
Assessments obtained previously  as part of routine clinical care may  be used as the baseline assessment as long as they were done no
more than [ADDRESS_1078000]-
treatment 
follow -up
visit
Study Day 1 2 3 4 7 11 15 22 29Every  7 day s 
until 
discharge or 
Day 6060
Visit window 
(± number of days)-[ADDRESS_1078001] 2 weeksXNSAIDs, antivirals, antibiotics, 
antimalarials, corticosteroids, cytokine -
directed therapy or other investigational 
treatments.
Tobacco use X Includes e-cigarettes.
Concomitant 
medicationsX X X X X X X X X X X X
Adverse events (AEs)
X X X X X X X X X X X X XAny events that occur after signing the 
informed consent are considered AEs as 
defined in Section 10.3.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
12Study 
J2W-MC - PYAAScreening Double -blind treatment and assessmentsDischarge 
from 
hospi[INVESTIGATOR_783853] -up if 
inpatient in
hospi[INVESTIGATOR_783854] 29Post-
treatment 
follow -up
visit
Study Day 1 2 3 4 7 11 15 22 29Every  7 day s 
until 
discharge or 
Day 6060
Visit window 
(± number of days)-2 2 2 2 2 2 2 4
Physical Evaluation or Clinical Assessments
Physical examinationXDocumentation of hospi[INVESTIGATOR_307] -based exam is 
acceptable.
Symptom -directed 
physical examX X X X X X X X X X XDocumentation of hospi[INVESTIGATOR_307] -based exam is 
acceptable.
Vital signs
X X X X X X X X X X X X XDocumentation of hospi[INVESTIGATOR_307] -based exam is 
acceptable.
Includes: temperature, pulse rate, BP, 
respi[INVESTIGATOR_697], SpO2, and where 
applicable FiO2. 
Day 1 timing: 
 immediately before the infusion, 
 every 15minutes during the infusion , 
as possible
 every 30 minutes for 2 hours after 
infusio nand
 every 1 hour for the next 4 hours after 
infusion .  
Automation may be used.
All other study days :once daily.
Single 12 -lead ECG 
(local) XDocumentation of hospi[INVESTIGATOR_307] -based exam 
within 72 hours prior to dosing is 
acceptable.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
13Study 
J2W-MC - PYAAScreening Double -blind treatment and assessmentsDischarge 
from 
hospi[INVESTIGATOR_783853] -up if 
inpatient in
hospi[INVESTIGATOR_783854] 29Post-
treatment 
follow -up
visit
Study Day 1 2 3 4 7 11 15 22 29Every  7 day s 
until 
discharge or 
Day 6060
Visit window 
(± number of days)-[ADDRESS_1078002] x- ray (local)
XDay 1: enter interpretation of most recent 
chest CT scan or x -rayin CRF if done .  No 
new imaging is required .
Hospi[INVESTIGATOR_48193]
X X X X X X X X X X XIncludes:
 hospi[INVESTIGATOR_057]
 ICU admittance, and 
 discharge
Clinical status and 
concomitant 
procedures of special 
interest
X X X X X X X X X X X XIncludes : 
Limitation on activities due to COVID -19
and requirements for:
 Ongoing hospi[INVESTIGATOR_446380]
 Supplemental oxygen
 Non-invasive ventilation or high flow 
oxygen device
 Mechanical ventilation
 ECMO
 Additional organ support ( e.g. 
pressors, renal replacement) , or
 Consciousness status (ACVPU) .
Clinical symptomsX X X X X X X X X X X XIncluding p resence of fever, cough, 
shortness of breath at rest or on exertion
Laboratory Tests and Sample Collection
Hematology
X X X X X X X X X XDocumentation of hospi[INVESTIGATOR_307] -based laboratory 
results are acceptable.
Local laboratory
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
14Study 
J2W-MC - PYAAScreening Double -blind treatment and assessmentsDischarge 
from 
hospi[INVESTIGATOR_783853] -up if 
inpatient in
hospi[INVESTIGATOR_783854] 29Post-
treatment 
follow -up
visit
Study Day 1 2 3 4 7 11 15 22 29Every  7 day s 
until 
discharge or 
Day 6060
Visit window 
(± number of days)-2 2 2 2 2 2 2 4
Clinical Chemistry
X X X X X X X X X XDocumentation of hospi[INVESTIGATOR_307] -based laboratory 
results are acceptable.
Local laboratory
eGFR X Local calculation using CKD -EPI
[INVESTIGATOR_783855] (LDH)X X X X X X X X XDocumentation of hospi[INVESTIGATOR_307] -based laboratory 
results are acceptable.
Local laboratory C-reactive protein X X X X X X X X X
Ferritin X X X X X X X X X
D-dimer X X X X X X X X X
Procalcitonin X X X X X X X X X
Troponin X X X X X X X X X
SARS -Cov -[ADDRESS_1078003] was reported for COVID -19 infection 
≤14 day s prior to randomization
Local laboratory
Serum pregnancyXOnly for WOCBP (Section 10.4 Appendix 
4)Local laboratory
Urine pregnancy XOnly for WOCBP (Section 10.4 Appendix 
4)Local laboratory
Pharmacokinetic (PK) 
sample
X X X X X X XDay 1: before the infusion andanytime just 
prior to the end of infusion .
All other scheduled samples may be taken 
at any  time during that scheduled day.  
Lilly -designated laboratory
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
15Study 
J2W-MC - PYAAScreening Double -blind treatment and assessmentsDischarge 
from 
hospi[INVESTIGATOR_783853] -up if 
inpatient in
hospi[INVESTIGATOR_783854] 29Post-
treatment 
follow -up
visit
Study Day 1 2 3 4 7 11 15 22 29Every  7 day s 
until 
discharge or 
Day 6060
Visit window 
(± number of days)-2 2 2 2 2 2 2 4
Immunogenicity 
(ADA) sample
X X X X X XDay 1:  before the infusion . 
All other scheduled and unscheduled 
immunogenicity samples should be 
collected with a time -matched PK sample .
Lilly -designated laboratory
Pharmacodynamic 
sample 
X X X X X X X X XSARS -Cov-2 swab 
Methods include nasopharygeal (preferred) 
or mid -turbinate.
The same method of sample collection 
must be used per participant for the 
duration of the study.  Switching methods 
is not allowed.
Day 1:  before the infusion.
Lilly -designated laboratory
Explo ratory  
biomarker samplesX X X X X X X X XDay 1: before the infusion
Lilly -designated laboratory
Pharmacogenetics 
sampleXLilly -designated laboratory
Randomization and Dosing
Randomization X
Administer study 
interventio n 
(IV infusion)X
Abbreviations:  ACVPU = alert, consciousness, verbal, pain, unresponsive scale; ADA = anti -drug antibody; BP = blood pressure; CKD -EPI = Chronic Kidney Disease 
Epi[INVESTIGATOR_151270]; CRP = C -reactive protein; ECG = electrocardiogram; ECMO = extracorporeal membrane oxygenation; ED = early discontinuation; FiO2 = 
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
16fraction of inspi[INVESTIGATOR_446364]; ICU = intensive care unit; IV = intravenous; NSAIDS = non- steroidal anti -inflammatory drugs; SARS -Cov-2 = severe acute respi[INVESTIGATOR_11520] 2; SpO2 = saturation of peripheral oxygen; WOCBP = women of child -bearing potential.  
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
172. Introduction
The efficient community spread of SARS -CoV -2has resulted in the current pandemic of COVID -19, 
which in severe and critical cases results in progressive pulmonary infection ,complicated by 
[CONTACT_15206][INVESTIGATOR_1399] ,with a high prevalence of acute respi[INVESTIGATOR_1505].  Although several 
therapi[INVESTIGATOR_783856] -19, none have improve dsurvival, including 
antivirals, glucocorticoids, and immunoglobulins (Liu et al 2020).
The SARS -CoV -2gains entry  to cells through binding of the spi[INVESTIGATOR_2531] (S) protein to ACE2 receptors 
on cells (Hoffmann 2020).  Eli Lilly and Co mpany has a partnership wit h AbCellera Bio logics 
Inc. (AbCellera; Vancouver, Canada) to develop neutralizing IgG1 monoclonal ant ibodies 
(mAbs) to the Spi[INVESTIGATOR_2531] (S) protein of SARS -CoV -[ADDRESS_1078004] been selected from a recent ly recovered COVID -19 
[LOCATION_002]patient’s serum using AbCellera’s core plat form screening technol ogies. 
LY3819253 is a neutralizing IgG1 monoclonal antibody (mAb) to the spi[INVESTIGATOR_119901]-
CoV -2.  It is designed to block viral attachment and entry into human cells ,and to neutraliz e the 
virus , potenti ally treating even established COVID -19 by  [CONTACT_4136] a specific potent, 
neutralizing ant ibodytoSARS -CoV -2.  The blocking of viral entry  into respi [INVESTIGATOR_783857], and vi ral neutralizati onis expected to mitigate the severit y of disease in pat ients 
in who m ongoing viral spread and replicat ionis the primary driver of COVID -19 
pathophysio logy.  The decrease in viral replic ation may  also shorten a pati ent’s extent and 
durati on of  viral shedding and transmissio n, posit ively impacting public healt h.  
2.1. Study Rationale
LY3819253 is a neutralizing IgG1 mAb to the spi[INVESTIGATOR_119901] -CoV -2.  It is designed to 
block viral attachm ent and entry  into hum an cells ,and to neutraliz e the virus , potenti ally treating 
even established COVID -19 by  [CONTACT_1541] a specific potent, neutralizing ant ibodytoSARS -CoV -
2.
Study  J2W-MC-PYAA (PYAA) aims to invest igate the safet y, tolerabilit y, PK,and PD of 
LY3819253 following a single dose administered to participants hospi [INVESTIGATOR_191544] -19.
The data from this study  will inform decisi ons for the clinical development of LY3819253 .
2.2. Background
The global spread of SARS-CoV -2 has resulted in the current pandemic of COVID -19, which in 
criticalcases resul ts in progressive pulmo nary failure , 
complicationswithARDS and can result 
in death.
The SARS -CoV -2gains entry  to cells through binding of the spi[INVESTIGATOR_2531] (S) protein to ACE2 receptors 
on cells ( Hoffmann 2020).  By  [CONTACT_53167] S protein, LY3819253 is designed to block 
interact ion with the ACE2 receptors, interfering with viral attachment and entry  into human 
cells, and is also desi gned to neutralize SARS
-CoV -2. These ant iviral effects are expected to 
resul t in a clinically  important decrease in viral replicat ion, mit igating the severit y of disease in 
patients f or whom  ongoing viral replicat ion is the primary driver of COVID -19 pathophysio logy.  
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
18Given the current public healt h emergency  and the urgency  to discover therapi [INVESTIGATOR_135297] -19, 
additional nonclinical efficacy  and safet y studi eswill be conducted in parallel wit h the first 
clinical studies.  Nonclinical data will be s hared as it beco mes available.
2.3. Benefit/Risk Assessment
LY3819253 has not been administered to humans.  N onclinical informat ion for LY3819253 is 
described in the Invest igator’s Brochure ( IB).  
The potential benefit to humans with COVID -19 disease is considered greater than the likelihood 
of anticipated and unant icipated risk.   
Anticipated risk is considered low and is based on the known mechanism o f action for human 
derived neutralizing ant ibodies in acute viral disease states.  LY3819253 consistsof a highly 
specific mAb directed at forei gn (non -human) epi[INVESTIGATOR_9230](s) and will be given to infected patients as 
a single dose in a controlled ,hospi [INVESTIGATOR_103139].  The complementarit y determining regions 
(CDRs) of the mAb were derived from B lymphocy tes of  a convalescent naturally SARS -CoV -2-
infected pati ent and, thus, have undergone natural posit ive and negat ive select ion pressures in 
vivo, unlike humanized ant ibodies generated in mice.  Therefore, off -target binding and tissue 
cross -reactivit y are considered unlikely.  
A theoretical risk is that LY3819253 may cause antibody -dependent enhancement (ADE) of viral 
replicat ion.  Thi s is based on responses observed to some monoclonal antibody  therap iesused in 
other unrelated viral diseases.  Unlike ADE associated with Dengue and Zika virus infect ions, 
this pheno menon has not been clearly established for coronaviral infect ions, such as SARS and 
MERS ,and has not been reported to date with SARS
-CoV -2.  Addit ionally, limited experience 
with the use of convalescent serum as a treatment for patients with severe COVID -19 di sease has 
not indicated safety  concerns ( Shen, 2020; Duan, 2020 ). LY3819 253will be administered to 
patients at sufficient ly high dose levels to neutralize SARS -CoV -[ADDRESS_1078005] therapeutic mAbs are the potenti al for 
infusio n-related hypersensit ivity and cy tokine rel ease reacti ons.  Thesingle infus ionin this study
will be at a controlled rate, the study  partici pants will be mo nitored in the hospi[INVESTIGATOR_6885], and 
adjustm ents in the infusio n rate will be made and/or the infusio n stopped, if indicated . 
Overall, these risks to patients with COVID- [ADDRESS_1078006] of care treatment, are considered monitorable and manageable in the hospi[INVESTIGATOR_6885] ,
and the potential benefit outweighs the risks.  
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected adverse events of LY3819253 may be found in the IB. 
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
193. Objectives and Endpoints
Objectives Endpoints
Primary
Characterize the safety and tolerability of 
LY3819253 after intravenous infusionSafety assessments such as AEs and SAEs
Secondary
Characterize the pharmacokinetics of 
LY3819253 after intravenous infusionLY3819253 mean concentration onDay 29
Characterize the pharmacodynamics of 
LY3819253 after intravenous infusionChange f rom baseline in SARS -CoV -2 viral 
load (Day s 7, 11, 15 and 2 2)
SARS -
CoV -2 viral load AUC
Time to SARS -CoV -2 clearance 
Tertiary/Exploratory
Characterize the participant’s clinical status Duration (days) of hospi[INVESTIGATOR_059]
Proportio n (percent age) of participants 
admitted to ICU
Proportio n (percent age) of participants 
requiring mechanical ventilation
Score using the NIAID and WHO ordinal 
scale sat pre -
specified time points
Proportio n (percent age)of pa rticipa nts with at 
least a 2 -point improvement on the NIAID 
and WHO ordinal scale or live discharge from 
hospi[INVESTIGATOR_783858] -specified time point s
NEWS2 score at pre -specified time points
Proportio n (percentage) of participants with 
anyworsening o n the NIAID ordinal scale 
from baseline to Day 15
Characterize the pharmacodynamics of 
LY3819253 after intravenous infusionProportio nof participants thatachieve SARS -
CoV-2 clearance (Day s 7, 11, 15, 22)
Characterize emergence of viral resistance to 
LY3819253Comparison from baseline to Day 29
Abbreviations:  AE = adverse event; ICU = intensive care unit; NIAID = National Institu te of Allergy and Infectious 
Diseases; NEWS2 = National Early Warning Score; SAE =serious adverse event; SARS -CoV -2 = severe acute 
respi[INVESTIGATOR_19960] 2; WHO = World Health Organization.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
204. Study Design
4.1. Overall Design
Study  PYAA is a Phase 1, double -blind, sponsor unblinded, rando mized, placebo -controlled, 
single
-ascending dose study .
Screening
Interested hospi[INVESTIGATOR_783859](s) prior 
to com pletion of  any procedures. Screening may be perform ed up to 48 hours prior to dosing.  
Screening and Da y1 may occur on the sam e day .
Double -blind Treatment and Assessment Period
This is the general sequence of events during the treatment and assessment period :
Participants are randomized to LY3819253 or placebo
Site completes baseline procedures and sample collect ion
Parti cipants begin a single IV infusio n of study  intervent ion, and
Site completes all safety monitoring and post-infusio n sample co llection.
Discharge from hospi[INVESTIGATOR_783860] m the hospi [INVESTIGATOR_783861] .  
If hospi[INVESTIGATOR_2345] … Then…
Occurs prior to Day 29 participants will be asked to complete the remaining 
study assessments at the timepoints indicated in the 
SoA.  
NOTE: Strategies to manage infection risks and reduce 
theburden of return visits should be consider ed by 
[CONTACT_21127], such as home visits .
Occurs on the same day as a study assessment visit hospi[INVESTIGATOR_783851] [ADDRESS_1078007] ion 6.6.1 .  
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
21Temporary  stoppi[INVESTIGATOR_783862] 6.6.[ADDRESS_1078008] 8 parti cipants : 
6 randomized to LY3819253 and 
[ADDRESS_1078009] 2 participants in each cohort will be rando mized 1:[ADDRESS_1078010] 4 day s after the IV infusio n by [CONTACT_1275] (s) and Lilly sponsor team.
Cohort [ADDRESS_1078011] reduction in the 
rate of clinical worsening .
In accordance with FDA recommendat ion (20 March 2020 Pre -IND Meeting), the population for 
this study  are hospi [INVESTIGATOR_783863] -CoV -2.  
Participants enrolling to this study will hav emoderate to severe COVID -19 illness according to 
the Food and Drug Administration (FDA) definit ions(FDA resource page [WWW]) , but wi th 
notabl e except ion in the specific eligibilit y criterion#21for severe pa rticipants.  Th isexception 
isintended to limit the severit y of the pa rticipan t enro lling to this study to excl ude those at 
highest ri sk of respi[INVESTIGATOR_33078] .  
Lilly believe sthe optimal benefit:risk for LY3819253 maybe 
found in a pa rticipan t that does not hav e impending respi[INVESTIGATOR_33078], as thi s severi ty 
of patients wi th COVID -[ADDRESS_1078012] ive. Further, adverse events 
in this populat ion coul d potent ially conf ound our abilit y to discern safet y signals in this stud y.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
22Remote follow -up visits may be conducted to remove the burden of return visits for the hospi[INVESTIGATOR_783864]-[ADDRESS_1078013] 3 cohorts will explore the efficacious dose range 
(2doses) and [ADDRESS_1078014] igated dose but will not exceed 7000 mg .
The doses are determined based on thesekey variables: 
projected human PK of the mAb , including l ung tissue distribut ion   
in 
vitro binding potency  to the vi ral targets
neutralizat ion of viruscell entry  and replicat ion, and 
antibody -viral dynamic modeling and simulation.  
The proj ected human half -life isexpected to be approximately  19 days based on PK/PD 
modeling .  
The starting dose of [ADDRESS_1078015] participant.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
235. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.   Due to the crit icality of part icipant health and 
the setting of this research study , verba l interview of a potenti al parti cipant, thei r legal 
representative or family member, may be the source for preexist ing condit ions and medical 
history  unless otherwi se specified wit hin the eligibilit y criteria.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1. A re≥18and ≤[ADDRESS_1078016] moderate or severe COVID -
19 illness per the 
FDA resource page ( WWW) ( Secti on 10.8, Appendix 8)
3.This criterion was removed
4.
Are hospi [INVESTIGATOR_057] , or in the process of being admitted to hospi[INVESTIGATOR_307], and have an init ial 
laboratory  determin ation of current COVID -19 infection ≤14days of randomizat ion.
Sex
5.Are me nor non -pregnant women
Reproductive and Contraceptive agreements and guidance is provided in Section 10.4, 
Appendix [ADDRESS_1078017] ion of nasopharyngeal swabs and venous blood
Informed Consent
9.The parti cipant or l egally  authori zed representative givesigned inform ed consent as 
described in Secti on10.1.3 ,which includes co mpliance with the requirements and 
restri ctions listed in the informed consent form (ICF) and in this protocol . 
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
10.Requi re invasive mechanical vent ilation or anticipate dimpending need for invasive 
mechanical vent ilation 
11.Anticipate transfer to another hospi[INVESTIGATOR_226289] a study  site wi thin 5 days of 
rando mizat ion
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
2412.Have known allergi es to any  of the com ponents used i n the formulat ion of the 
intervent ions
13.Have hemodynamic instabilit y requiring use of pressors within [ADDRESS_1078018] ion (besides 
COVID -19) that i n the opi[INVESTIGATOR_3078] n of the invest igator could const itute a ri sk when taking 
intervent ion
16.Have any co -morbidity requiring surgery  within <[ADDRESS_1078019] prior history  of hepati c impai rment,such as 
a.severe liver cirrhosis Child -Pugh B or worse 
b.cirrhosis wi th a history  of hepatic encephalopathy  
c.clinically meaningful ascites requiring ongoing treatment with d iuretics and/or 
paracentesis, or 
d.history  of hepatorenal syndrome.
18.Have a ny serious concomi tant sy stemic disorder that, in the opi[INVESTIGATOR_3078] n of the investigator, 
woul d precl ude parti cipat ion in the study
19.Current diagnosis of act ive malignancy that, in the opi[INVESTIGATOR_3078] n of the invest igator, could 
constitute a risk when taking invest igational product
20.Received convalescent COVID -[ADDRESS_1078020] an SpO2 <88% while breathing room air at rest . If on suppl emental  oxygen at the 
time of screening, usethe last time point of measurement on room air up to [ADDRESS_1078021] alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5X upper 
limit of normal (ULN)
24.Have acute kidney disease with an eGFR < 30 m L/min/1.73 m2based on the chronic 
kidney disease epi[INVESTIGATOR_783865] 
(CKD -EPI).
Chronic kidney  disease is all owable, if judged to be stable for the past 3months, in the 
opi[INVESTIGATOR_3078] n of the invest igator.
Other Exclusions
25.Are pregnant or breast feeding
26. A reconcurrent ly enrolled in any other type of medical research judged not to be
scientifically or medically co mpatible wit h this study
27. A re Lilly  empl oyees
28. A re invest igator site personnel directly affilia ted wi th this study  or thei r immediate 
families.  
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
255.3. Lifestyle Considerations
Reproductive and Contraceptive guidance is provided in Section 10.4, Appendix 4.
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently enrolled in the study . 
Repeat ing laboratory tests during the screening period does not constitute rescreening.
Individuals who do not meet the criteria for participation in this study  (screen failure) may notbe 
rescreened. 
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
266. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to /used by a study  parti cipant 
according to the study  protocol .
6.1. Study Intervention(s) Administered
This is a single dose study .  
Intervention Name s LY3819253 Placebo
Type Biologic Not applicable
Dose Formulation solution 0.9% Sodium chloride solution
Unit Dose Strength(s) 700 mg/vial Placebo
Planned Dosage Level(s) Cohort 1:  700 mg
Cohort 2:  2800 mg
Cohort 3:  7000 mg
Optional Cohort 4 may explore lower or 
equal levels to the max investigated 
dose, but will not exceed 7000 mg.Not applicable
Route of Administration IV infusion IV infusion
Use experimental placebo
IMP and NIMP IMP IMP
Sourcing From Lilly Commercially available 0.9% sodium 
chloride solution will be used as a 
placebo for this study
Packaging and Labeling Study Intervention will be provided in 
glass vials and will be labeled 
appropriatelyCommercially available 0.9% sodium 
chloride solution will be used as a 
placebo for this study
Abbreviations:  IMP = investigational medicinal product ; NIMP = non -investigational medicinal product .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
27This table describes the infusio n volume and rate for the planned LY3819253 doses .  Coh ort 4 
instructi ons will  be provi ded in the pharmacy  instructi ons.  Placebo vo lume and rate will match 
the LY3819253 dose cohort.
LY3819253 Dose (mg) Volume (mL) Start Infusion rate x Time
700 50 100 mL/hr x 30 min
2800 75 100 mL/hr x 45 min
7000 100 100 mL/hr x [ADDRESS_1078022] 4 hours after the complet ion of  the infusio n.
6.1.1. Special Treatment Considerations
[IP_ADDRESS]. Premedication for Infusions
Prem edicat ion for infusio ns is not pl anned.  However, if an infusion react ion occurs during 
administration or if the pa rticipant has a medical history  suggesting a potential benefit from 
prem edicat ion, the study  invest igator(s ) should determine the appropriate premedication.
The invest igator sand sponsor may decide to usepremedicat ion for other cohorts if the frequency 
of infusio nreacti ons am ong parti cipants warrants it .
If minor infusio n reactions are observed, but review of the data suggests that dose escalation may 
continue, administration of acetaminophen, 500 mg to 1000 mg , antihistamines and/or other 
appropriately  indicated medicationsmay be given pri or to the start of infusio nsfor subsequent 
participants. 
The decisio n to implement premedicat ion for infusio ns in subsequent cohorts will be made by 
[CONTACT_783881], along w ith the dose -
escalat ion decisio n.  
Any premedicat ions given will be documented as a concomitant therapy .
[IP_ADDRESS]. Management of Infusion Reactions
All participants shoul d be m onitored cl osely , asthere is a risk of infusio n reaction and 
hypersensit ivity (incl uding anaphylaxis) with any bi ological  agent.  
Symptoms and Signs
Symptom s and si gns that m ay occur as part of an infusio n reaction include, but are not limited to 
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash
including urticaria , pruri tus, myalgia, and dizziness.  
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
28Infusio n-related reacti onsseveri tywill be assessed and reported using the Divisio n of Allergy 
and Infect ious Diseases ( DAIDS )Table for Grading the Severit y of Adult and Pediatric Adverse 
Events, version 2.1 (July 2017) .
This table describes the severit yof react ions according to DAIDS .
Parameter Mild Moderate Severe Severe and 
Potentially 
Life-threatening
Acute 
Allergic 
ReactionLocalized urticaria 
(wheals) with no 
medical intervention 
indicatedLocalized urticaria 
with intervention 
indicated 
OR 
Mild angioedema with 
no intervention 
indicatedGeneralized Urticaria 
OR
Angioedema with 
interventio n indicated 
OR
Symptoms of mild 
bronchospasmAcute anaphylaxis 
OR 
Life-threatening 
bronchos pasm 
OR
Laryngeal edema
Cytokine 
Release 
SyndromeaMild signs and 
symptoms 
AND
Therapy , that is, 
antibody infusion 
interruption not 
indicatedTherapy  indicated
(that is, antibody 
infusion) interruption 
indicated
AND
Responds promptly to 
symptomatic 
treatment
OR
Prophy lactic 
medications indicated 
for ≤24 hoursProlonged severe 
signs and symptoms 
OR
Recurrence of 
symptoms following 
initial improvementLife-threatening 
consequences 
(for example, 
requiring pressor or 
ventilator support)
a= A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and/or shortness of breath.
Source:  Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 
2.1(July 2017) .
Site Needs
The clinical site sho uld have necessary  equipment and medicat ions for the m anagement of any 
infusio n reaction, which may include but is not limited to oxy gen, IV fluid, epi[INVESTIGATOR_238], 
acetaminophen and ant ihistamine.
Management of Infusion Reaction s
Invest igators should determin ethe severi ty of the infusio n reaction andmanage infusion 
reacti ons based on standard of care and their clinical  judgment .  If an infusio n react ion occurs, 
then supporti ve care should be used in accordance with the signs and symptoms.
If a participant pe rmanent ly discontinues fro m study  intervent ion, they  shoul dcomplete adverse 
event ( AE)monitoring and other procedures as stated in the SoA.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
[IP_ADDRESS]. In the Event of a Retrospective Positive Sterility Finding from Prepared Study 
Intervention
If apositive sterili tyfindin goccurs in the terminally steril efiltered study  intervent ion,the
participants who were dosed fr om th e impacted batch shou ldbe contact[CONTACT_90734] a full physical examina tionincluding, but not limited to, blood pressure, pulse rate and 
body temperature . 
A bloodsampleshould be c ollected for culture and assayed for inflammatory markers such as 
C-reactive protein and eleva tions in white bl ood cell count s.
If the signs and symptoms indicated a participant has a possible infec tion, theywill be clinically 
managed, treated and f ollowed up un til resolution. Anyadverse events will be recorded as 
appropriate. 
6.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are reported 
and reso lved before use of the study  intervent ion.
To protect blinding, the intervent ionsmust be prepared by [CONTACT_783882] -related procedures.   
Instructi ons for preparation will be provided by  [CONTACT_456].
Only participants enro lled in the study  may receive study  intervent ion and only authorized site 
staff may supply or administer study  intervent ion. 
All study  intervent ion must be stored in a secure, environmentally controlled, and monitored 
(manual  or autom ated) area i n accordance with the labeled s torage condi tions wi th access limited 
to the invest igator and authorized site staff.
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record m aintenance (i .e., 
recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons are 
provi ded in the pharmacy m anual .
6.3. Measures to Minimize Bias: Randomization and Blinding
This is a blinded study .  
All participants will be centrally rando mized to study  intervent ion using an Interactive Web 
Response Sy stem  (IWRS). Before the study is init iated, the l og in informat ion anddirections f or 
the IWRS will be provided to each site.
This table describes general procedures for unblinding.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
30Unblinding (IWRS) Emergency unblinding for adverse events may be performed through the 
IWRS.  All actions resulting in an unblinding event are recorded and 
reported by [CONTACT_8784]
In case of an emergenc y, the investigator has the sole responsibility for 
determining if unblinding of a participants’ intervention assignment 
iswarranted
Participant safety must always be the first consideration in making such a 
determination. However, the investigator shoul d make all attempts to 
contact [CONTACT_783883]
If a participant’s intervention assignment is unblinded, the sponsor must be 
notified immediately after breaking the blind even if consultation occurred 
in advance
The date and reason that the blind was broken must be recorded in the 
source documentation and case report form.
Abbreviations:  IWRS =interactive web -response sy stem.
If an invest igator , site personnel performing assessments, or participant is unblinded while the 
infusio n is ongoing , the parti cipant m ust be discontinued from the study intervent ion and the 
infusio n stopped. If any amount of study  interventio n was administered, follow procedures 
according to the SoA as described in Section 7.1.
6.4. Study Intervention Compliance
Participants will receive study  intervent ion directly fro m the invest igator or designee, under 
medical supervisio n.  The date and time of each dose administered will be recorded in the source 
docum ents and recorded in the case report form ( CRF).  
6.5. Concomitant Therapy
Prior Treatment for Indication
Any pri or therapy , such as antivirals, antibiot ics, orantimalarials used as treatment prior to 
signing informed consent should be recorded.
Therapy  prior to enrol lment with ant ivirals including lopi[INVESTIGATOR_054]/ritonavir , rem desivir or other 
therapeuti c agents (e.g. corticosteroids) are permitted. 
Convalescent COV ID-[ADDRESS_1078023] of 
care for participants hospi[INVESTIGATOR_447845] (if available through the FDA Emergency 
Use Authorizat ions) outsi de of l ocal standard of care per written policies or guidelines.
If the local standard of care per written policies or guidelines (that i s, not j ust an individual 
clinician decisio n) includes lopi[INVESTIGATOR_054]/ritonavir, chloroquine, hydroxychloroquine or other 
investigat ional agents, then init iating these during the study is permitted, but may require 
additional safety  monitoring by [CONTACT_779].
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
31Convalescent COVID -[ADDRESS_1078024] igational agent, or vaccine ,including over the counter or prescript ion 
medicines, vitamins, and/or herbal supplements, or other specific categories of interest thatthe 
participant is receiving at the time of enro llment or receives during the study  must be recorded 
along wi th:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency for concomitant therapy  of special  
interest
Acetaminophen and corticosteroid use are permitted at any t ime during the study .
Other concomitant medicat ion may be considered on a case -by-case basis by [CONTACT_783884] .
The sponsor should be contact[CONTACT_447872] .
6.6. Dose Modification
6.6.1. Dose Escalation Criteria
By [CONTACT_105338] a Phase [ADDRESS_1078025] 4 day s after the IV infusio n by [CONTACT_093] (s), Lilly sponsor team and an 
independent safet y assessment committee (ISAC) .
The invest igator ,Lilly sponsor team and ISAC are responsible for determining any dose 
decisions.  The invest igator (s)will remain blinded and the Lilly sponsor team and ISAC will be 
unblinded during these reviews.   All available data from previous cohorts will be reviewed .  
Available PK and PD data m ay also be used to guide dose adjust ment. 
If temporary  stoppi[INVESTIGATOR_783852] m et (Secti on 6.6.2 ), dosing will be temporarily stopp edand no 
further participants will be dosed until a full safety review of the study  has taken place .  The 
ISAC will be engaged for the full safet y review with the sponsor and invest igator.  
6.6.2. Temporary Stoppi[INVESTIGATOR_783866], an d no f urther parti cipants will be dosed unt il a full safet y 
review of the study  has taken pl ace if:  
Two or more participants at a given dose level develop severe or severe/potentially life -
threatening acute AEs rel ated to the infusio n (see Table in Sect ion [IP_ADDRESS] ), during or 
within 2 hour of complet ion of the infusio n, that do not resolve wit h a reduced infusio n 
rate and/or supportive care. 
OR
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
32Two or more participants at a given dose level develop severe acute AEs within [ADDRESS_1078026] igator ,cannot be attributed to the primary 
disease, concomitant medicat ions or extraneous circumstances with a reasonable 
possibilit y.
This table describes the location of AE -related info rmation in this protocol.
Topic Location
DAIDS table describing severity of reactions Section [IP_ADDRESS]
Definitio n of AEs Section 10.3.1
Assessment of Intensity/Severity Section 10.3.[ADDRESS_1078027] be appropri ately docum ented and communicated 
with the study  personnel and the IRB/IEC before dosing cont inues.   
6.7. Intervention after the End of the Study
No continued access is planned after completion of this study ,as addit ional efficacy would be 
needed to demonstrate continued access criteria.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
337. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
These sections describe reasons for a participant’s
perm anent or tem porary  discont inuat ion ofstudy  drug, or
discontinuat ion (wi thdrawal) from  the study .
Discontinuati on of  specific sites or of the trial as a who le are handled as part of regulatory, 
ethical, and trial oversight considerat ions in Section10.1. Appendix 1.
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a participant to perm anent ly discont inue study  
intervent ion. If the IV infusio n is permanent lystopp ed, the participant willremain in the study  
for follow-up and further evaluat ions as described in the SoA .
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study  
at any  time at his/her own request 
at the request of his/her designee (for example, parents or legal guardian)
at the discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons
if the participant beco mes pregnant during the study
if enro llment in any other clinic al study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
See the SoA for data to be collected at the time of study discont inuat ion and fo llow-up and for 
any further evaluations that need to be completed
.  The participant will be permanent ly 
discontinued both from  the study  intervent ionand fro m the study  at that time .
If the participant withdraws consent for disclos ure of  future inform ation, the sponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent .  If a participant
withdraws fro m the study , theymay request destruction of any  samples taken and not tested ,and 
the invest igator must document this in the site study records .
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  treatm ent unl ess 
there are extenuating circumstances that make it medically necessary for the participant to 
continue study  treatm ent.  
If the invest igator and the sponsor CRP agree it is medically appropriate to continue, the 
investigator must obtain documented approval from the sponsor CRP to allow the inadvertently 
enrolled participant to continue in the study with or without treatment with investigational 
product. 
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
34Safety follow up i s as outlined in 
Secti on 1.3(Schedule of Act ivities), 
Secti on 8.2(Safet y Assessments), and 
Secti on 8.3(Adverse Events and Serious Adverse Events).
7.3. Lost to Follow up
A participant will be considered lost to follow -up if, after di scharge fro m the hospi [INVESTIGATOR_307], they  do
notreturn for scheduled visits and areunable to be contact[CONTACT_17066].Site personnel 
are expected to make diligent attempts to contact [CONTACT_10971] a scheduled 
visit or were otherwise unable to be fo llowed up by  [CONTACT_4179].
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
358. Study Assessments and Procedu res
Study  procedures and their timing are summarized in the SoA (Secti on 1.3).
Protocol waiver s or exem ptions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant sho uld cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participant s screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
8.1. Efficacy Assessments
This sect ion is not applicable for this study.
8.2. Safety Assessments
8.2.1. Physical Examinations
A complete physical examinat ionwill be performed at the screening visit. This examinat ion 
excludes pelvic, rectal, and breast examinat ionsunless clinically indicated.
A symptom -directed physical  examinat ion will be performed at other visits, as specified in the 
SoA and as clinically indicated.
Invest igators should pay special attention to clinical signs related to COVID -19, to ongoing 
medical condit ions and to previous serious illnesses.
8.2.2. Vital Signs
Vital signs will be measured as specified in the SoA and as clinically indicated .  Vital signs 
include
Body  temperature
Blood pressure
Pulse rate
Respi[INVESTIGATOR_1487]
Saturati on of  peripheral  oxygen , and
Suppl emental  oxygen flow rate , FiO2 if known, and method of delivery, if applicable .
Addit ional vital signs may be m easured during the study  if warranted, as determined by [CONTACT_1275].
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
368.2.3. Electrocardiograms
A single , local, 12- lead electrocardi ogram  (ECG )will be obta ined as outlined in the SoA using 
an ECG m achine that autom atically  calculates the heart rate and measures pulse rate , QRS, QT, 
and corrected QT intervals. Additional ECG readings may occur at i nvest igator discretion .
8.2.4. Clinical Laboratory Assessments
See Secti on 10.2, 
Appendix [ADDRESS_1078028] any  
clinically relevant changes occurring during the study  in the AE section of the CRF. 
Docum entati on of  the review may  be com pleted according to i nstitution processes or by  [CONTACT_783885]’ progress notes ( medical record )stating that the laboratory results 
have been reviewed.  
The l aboratory  reports m ust be filed wit h the source documents unless a source document 
agreem ent or com parable docum ent ci tes an electroni c locati on that accommodates the expected 
retenti on durati on. 
If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are considered 
clinically significant by  [CONTACT_17062] (e .g., serious adverse event [ SAE ]or AE or dose 
modificati on), then the resul ts must be recorded in the CRF.
Pregnancy Testing
Women of childbearing potential (WOCBP) m ust undergo p regnancy testing according to the 
SoA.  Participants who are pregnant will be discontinued fro m the study (Secti on 7.2). 
8.2.5. Hospi[INVESTIGATOR_783867], admitted to the ICU, discharge d from theICU, di scharged from  thehospi [INVESTIGATOR_307], 
admitted to an extended care facilit y, discharged to home .
8.2.6. Procedures of Special Interest
The parti cipants’ clinical status and concurrent procedures of special interest will be recorded in 
the CRF and include limitationon activit ies due to COVID -19and requirements for
ongoing hospi[INVESTIGATOR_446380]
supplemental  oxygen
non-invasive vent ilation or a high flow oxygen device
mechanical  ventilation
ECMO
additional organ support ( e.g. pressors, renal replacement) , or
consciousness status using alert, consciousness, verbal, pain, unresponsive scale
(ACVPU).
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
378.2.7. Respi[INVESTIGATOR_446381] , parti cipants m ay be managed wit h high -flow nasal  cannula, 
noninvasive posit ive pressure vent ilation or any  other form respi [INVESTIGATOR_446382].
8.3. Adverse Events and Serious Adverse Events
AEswill be reported by  [CONTACT_41413], when appropriate, by  a caregiver, surrogate, or the 
participant's legally  authori zed representative.
The i nvest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study procedures, or that 
caused the participant to discont inue the study  intervent ion or study .
Discontinuati on informat ion is in Section 7.
Detailed AE definit ions and procedures are in Sectio n 10.[ADDRESS_1078029] to different reporting requirements detaile d in 
Secti on 10.3.1 . 
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All AEs and SAEs will be collected from the time of signing of  the informed consent form (ICF)
until participation in the study  has ended.
Adverse events that begin before the start of study  intervent ion but after signing of the ICF will 
berecorded on the Adverse Event CRF.
Although all AEs after signing the ICF are recorded by [CONTACT_29558]/electronic data entry, 
SAE reporting to sponsor begins after the pa rticipa nt has signed the ICF and has received study  
intervent ion.  However, if an SAE occurs after signing the ICF, but prior to receiving study  
intervent ion, it needs to be reported within the SAE reporting t imeframe if it is considered 
reasonably  possibly  related to study  procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed [ADDRESS_1078030] igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she con siders the event to be reasonably  
related to the study  intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Section 10.3.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
38Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the participant is the preferred method to inquire about AE
occurrences .
8.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subs equent visits/contacts. All SAEs will be followed until reso lution, stabilizat ion, the event 
is otherwi se explained, or the participant is lost to fo llow-up (as defined in Sect ion7.3). Further 
inform ation on fo llow-up procedures is provi dedin Secti on10.3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_32847] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the saf ety of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB)/Independent Ethics Committees 
(IEC) , and invest igators.
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informa tion (e.g., summary  or list ing of SAEs) from the sponsor will review and then file 
it with the Investi gator’s Brochure ,and will notify the IRB/IEC, if appropriate according to local 
requi rements.
8.3.5. Pregnancy
Although normal pregnancy  is not an adverse event, d etails o f all pregnancies in female 
participants will be co llected for [ADDRESS_1078031] ion occurs, a dditional details describing each symptom should be provide dto the 
sponsor in the infusio n
-related reacti on/hypersensitivit y CRF . 
If symptoms and/or signs occur during or wi thin [ADDRESS_1078032] ively .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
39Sites shoul d have appropri ately  train ed medical staff and appropriate medical equipment 
available when study  parti cipants are receiving intervent ion. It is recommended that participants
who experience a systemic hypersensit ivityreact ion be treated per the local standard of care .  
In the cas e of generalized urti caria or anaphylaxis, addit ional blood and urine samples should be 
collected as described in Section 10.6, Appendix 6, “ Reco mmen ded Laboratory  Testing for 
Hypersensi tivity Events”. Laboratory results are provided to the sponsor via the central 
laboratory . 
In case of skin lesio ns or rash consistent with vasculit is, efforts should be made to perform the 
following as soon as possibl e
derm atology consul tation
skin biopsy , and
photographs of lesio ns of interest, including skin biopsy site .
8.3.7. Infusion -related Reactions
As wi th other mAbs, infusio n-related reactions may  occur during or following LY3819253
administration . If an infusio n-related reacti on occurs, addi tional data describing each symptom 
and sign should be provided to the sponsor in the CRF.  
This table describes the location of infusio n-related reacti on inform ation in this protocol.
Topic Location
Special treatment considerations Section 6.1.1
Premedication for infusions Section [IP_ADDRESS]
Management of infusion reactions Section [IP_ADDRESS]
DAIDS table describing severity Section [IP_ADDRESS]
Symptom s occurring during or after infusio n of study  intervent ionmay also be defined according 
toAE categories such as acute allergic reacti onor cy tokine release syndrome ( refer to DAIDS ).
8.3.8. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effect iveness o r performance o f a 
trial intervent ion. 
The s ponsor collects product complaints on study  intervent ionsused in clinical studies in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facili tate process and product 
improvements.
Parti cipants will be instructed to contact [CONTACT_783886].
NOTE: Any AEs or SAEs that are associated with a product complaint will fo llow the processes 
outlined in Sect ion 8.3.[ADDRESS_1078033] complaints that resul t in an adverse event will be detected, documented, and reported to 
the spo nsor during all periods of the study in wh ich the study  interventi onis used.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
40If the inv estigator l earns of any product com plaint at any  time after a participant has been 
discharged from  the study , and such incident is considered reasonably related to the study  
intervent ion, the investigator will prompt ly notify the sponsor.
Prompt Reporting of Product Complaints to Sponsor
Product complaints will be reported to the sponsor within [ADDRESS_1078034] igator is responsible for ensuring that fo llow-up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the product complaint .
New or updated informat ion will be recorded on the originally co mpleted form wit h all changes 
signed and dated by [CONTACT_783887] .
8.4. Treatment of Overdose
In case of suspected overdose, participants should be mo nitored for any  signs or symptom s of 
adverse reactions or effects, and supportive care should be provided as necessary. 
8.5. Pharmacokinetics
Venous blood samples will  be collected as specified in the SoA for determination of 
concentrations of LY3819253 used to evaluate the PK forLY3819253 .  
A maximum of 3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agr eed upon between the invest igator and the sponsor.
Instructi ons for the collect ion and handling of bio logical samples will be provided by [CONTACT_11007] . 
Site personnel will record
The date and time (24-hour clock time) of administrati on (start and end of infusi on), and
The date and time (24 -hour clock time) of each PK sample.
It is essent ial that the times are recorded accurately.   
8.5.1. Bioanalytical
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_17077] a facilit y 
designated by  [CONTACT_456]. Concentrations of LY3819253 will be assayed using a validated 
bioanalyt ical method.  Analyses o f samples co llected fro m placebo -treated subjects are not 
planned.
Sample retenti on is described in Appendix 1, Section 10.1.12.   Remaining samples used for PK 
may be pooled and used for exploratory  metabo lism or bioanaly tical method experiments as 
deem ed appropri ate.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
418.6. Pharmacodynamics
The SARS -CoV -[ADDRESS_1078035] ion 10.1.12 .  Remaining samples may  be used fo r addi tional 
exploratory  studi es to better understand LY3819253 and the disease , which may  include 
sequencing and/or culture of the virus for future studies .
8.7. Genetics
A who le blood sample will be co llected for pharmacogenet ic analysis where local regulat ions 
allow.   
See Secti on10.2 Clinical Laboratory  Tests, and Secti on 1.3SoA for sample co llection 
inform ation.  
SeeSecti on10.5 for genetic research ,custody , and sam pleretenti on informat ion.
8.8. Biomarkers
Blood sam ples will be collected from all participants for analysis o f immune system -related 
markers. Serum, who le blood for cellular and /orepi[INVESTIGATOR_446383], and whole blood RNA 
samples for exploratory  biomarker research will be collected at the time specified in the SoA 
where local regulat ions allow. 
Samples will  be stored and analysis may  be performed on bio marker sthought to pl ay a rol e in 
immune system related responses to viral infect ionincluding, but not limited to , immune 
pathways , cellular compos ition, serum  analy tes, or epi[INVESTIGATOR_783868] ,to eval uate thei r 
associ ation with observed clinical responses to LY3819253 and the disease state .  
Samples may  be used for research to develop methods, assays, prognostics and/or companio n 
diagnosti cs rel ated to the intervention target (S protein) , the COVID -19 di sease state , pathways 
associ ated wi th disease, and/or the mechanism of action of the study  intervent ion.
Sample retenti onis described in Section10.1.12.
8.9. Immunogenicity 
Visits and times
At the visit s and t imes specified in the SoA, venous bl ood sam ples will  be collected to determine 
antibody  producti on against LY3819253 .  The actual date and time (24- hour clock time) of each 
sample collect ion will be recorded.
Sample collection, handling, and use
Instructi ons for the collect ion and handling of blood samples will be provided by [CONTACT_456].
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
42Immunogenicit y will be assessed by  a validated assay  designed to detect ADAs in the presence 
of LY3819253 at a laboratory approved by  [CONTACT_456].  Antibodies may be further characterized 
for their abili ty to neutralize the activit y of LY3819253.   
Sample retention
Sample retenti onis described in Section10.1.[ADDRESS_1078036] ion is not applicable for this study.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
439. Statistical Considerations
9.1. Statistical Hypotheses
This is an exploratory  study  with a primary  objective of assessing safet y and tol erabilit y.  Any 
hypothesis tests conducted for treatment comparisons will be exploratory  in nature and 
conducted without adjustment for m ultiplicity.
9.2. Sample Size Determination
For Cohorts 1 –
3, approximately 24participants will be rando mized to receive one of three dose 
levels o f LY3819253 or placebo.  Addit ional participants may be required to ensure a minimum 
of 8 parti cipants in each cohort complete 7 days of study  assessments . Up to a maximum o f 3 
additional parti cipants per cohort may be added .
Participant viral loads over time were s imulated using a representative PK /PD m odel to enable a 
Monte Carlo assessment of the power of the trial to detect a 30% treatment difference in mean 
AUC (28 day ) of viral load.  Thi s assessment revealed greater than 90% p robabilit y of meet ing 
the following Bayesian cri tical success factor:  
Pr (
(mean AUC PL–mean AUC LY)/ mean AUC PL> 0.3) > 0.60
PL = pla cebo, LY = LY3819253   
Addit ionally , the ant icipated 6 pa rticipants per treatm ent provides greater than 80% probabilit y 
(within each treatm ent arm ) of observing safet y events of reasonable prevalence ( that is, at least 
25%) to support the primary  object ive of safet y assessment .  
For the opti onal Cohort 4, up to 100participants may be rando mized in an approximate 1:1 ratio 
to receive either LY3819253 or placebo.  The overall numbers of pa rticipants rando mized to 
LY3819253 and placebo in this study  will provi de 60% power to detect a reduction in the rate of 
clinical worsening fro m 22% to 9% (one -sided alpha=0. 05).  Clinical worsening is defined as the 
proporti on (percentage) of participants with any worsening on the NIAID ordinal scale fro m 
baseline to Day  15.
A participant i s only allowed to receive oneIV infusion in onecohort.
9.3. Populations for Analyses
T
his table defines the populations for analysis.
Population Description
Entered All participants who sign the informed consent form
Safety All participants randomly assigned and who received study intervention. 
Participants will be analyzed according to the intervention they actually  
received .
Pharmacokinetic All randomized participants who received study intervention and have 
evaluable PK sample. Participants will be analyzed according to the 
interventio n they actually received .
Pharmacodynamic All randomized participants who rec eived study intervention and provided at 
least o ne post -baseline measure for the relevant endpoint. Participants will be 
analy zed according to the intervention they actually  received .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
449.4. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y ofsponsor or its designee .
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol.  Any other change to the data analysis 
methods described in the p rotocol , and the j ustification for making the change, will be described 
in the statist ical analysis plan ( SAP).  Addi tional expl oratory  analyses of the data will be 
conducted as deemed appropriate.
The SAP will be finalized prior to the first pa rticipant dosed and it will include a more technical 
and detailed descript ion of the statistical analyses described in this sect ion. This sect ion is a 
summary of the planned statist ical analyses of the most important endpoints including primary 
and key  secondary e ndpo ints.
9.4.1. General Considerations
This table describes the general statist ical methods that m ay be used in this study .
Method Analysis 
Descriptive Statistics number of participants, mean, standard deviation, 
median, minimum, and maximum for continuous 
measures, and frequency counts and percentages for 
categorical measures
Kaplan -Meier curves and summary statistics Time-to -event analysis
Logistic regression analysis Treatment comparisons of binary variables with 
treatment in the model.
Nonparametric 
(for example, Mann -Whitney or van Elteren tests)Treatment comparison of ordinal variables .
Analy sis of variance or analysis of covariance Treatment comparisons of continuous variables 
following appropriate transformations , if necessary
Adjustments for other factors , if any, will be described in the SAP.
9.4.2. Safety Analyses
Safety analyses will be conducted using the safet y popul ation described above. 
All invest igational product and protocol procedure AEs will be listed, and if the frequency o f 
events allow s, safet y data will be summarized using descript ive methodol ogy.
The incidence of AEs for each treatment will be presented by  [CONTACT_447875]. Adverse events reported prior to randomizat ion
will be dist inguished from those reported as new or increased in severit y during the study post-
rando mizat ion.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
45Safety param eters that will be assessed include, but are not limited to, safet y laboratory  
param eters, and vital signs. The parameters will be summarized using standard descriptive 
statist ics.Addit ional analysis will be perform ed if warranted upon review of the data .
9.4.3. Pharmacokinetic and Pharmacodynamic Analyses
Pharmacokinet ic analyses will be conducted on data fro m all participants who receiv e 
intervent ion and have evaluable PK.
Pharmacokinet ic parameter estimates for LY3819253 will be calculated using standard 
nonco mpart mental methods of analysis.
The primary  parameter for analysis will be mean concentration on Day  29.  Other 
nonco mpart mentalparam eters, such as half -life, apparent clearance, and apparent volume of 
distribut ion, may be reported. 
Pharmacodynamic endpo ints will be summarized using descript ive methodol ogy.
The SARS -CoV -2 viral dynamics will include evaluation of
Change from baseline in SARS -CoV -2 viral load(Days 7, 11, 15 and 22)
Viral load AUC
Time to SARS -CoV -2 clearance , and
Proporti on of  participants that achieve SARS -CoV -2 clearance .
Addit ional PK/PD concentration -response analysis may  be perform ed.  
9.4.4. Exploratory Endpoint s
Exploratory  endpo ints will be summarized using descript ive methodol ogyand treatm ent 
comparisons conducted using methods previously  described .
Endpoints will include :
Durati on (days) of hospi[INVESTIGATOR_3094]
Proporti on (percent age) of participants a dmitted to ICU
Proporti on (percent age) of participants requiring mechanical vent ilation
Score on the NIAID ordinal scale at pre -specified time points
Score on the WHO ordinal scale at pre -specified t ime point s
Proporti on (percentage) of participants with at least a 2 -point improvement on the WHO 
ordinal scale or live di scharge from  hospi[INVESTIGATOR_307], at pre -specified time po ints
Proporti on (percentage )of participants with at least a 2 -point improvement on the NIAID 
ordinal scale or live discharge from hospi[INVESTIGATOR_783858]-specified timepoints
NEWS2 score at pre-specified time points
Proporti on (percentage) of participants with any worsening on the NIAID ordinal scale 
from baseline to Day  15, 
and
Com parison from  baseline to Day  29 for the emergence of viral resistance to LY3819253 .
Mortalit y and categorical changes on the ordinal scale will be analyzed as discrete variables.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the resul ts of other studies f or safet y, pharmacodynamic, or 
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
46popul ation PK analysis purposes to avoid issues with post -hoc analyses and inco mplete 
disclosures of analyses.
9.4.5. Immunogenicity
If data fro m validated immunogenicit y assays are available , treatm ent-emergent anti -drug 
antibodies (TE-ADAs) maybe assessed. 
Treatment -emergent ADAs are defined as participants
with a 2-fold (1 dilution) increase in t iter than the minimum required dilut ion if no ADAs 
were detected at baseline (treatment -induced ADA) or 
with a 4-fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatment -boosted ADA).
The frequency and percentage of participants with preexist ing ADA and who are TE -ADA 
positive (TE -ADA+) to LY3819253 will be tabulated.   
The distribut ion of titersand frequency o f neutralizing ant ibodies (if assessed) for the TE -ADA+ 
participant smay also be tabulated.
The rel ationship between the presence of ant ibodies and PK parameters ,PD response orsafet y to 
LY3819253 may also be assessed. Addit ionaldetails may  be provided in the SAP.
9.5. Interim Analyses 
Periodic, unblinded reviews of PK, PD and safety  data will  occur throughout the study in 
addition to the scheduled dose escalat ion reviews .
If Cohort 4 proceeds, then up to 4 interim analys es may occ ur.  
Moni toring of unblinded safet y data (including AEs, SAEs, and selected laboratory
measurements) will occur throughout the study  and will be conducted by  [CONTACT_208194] . Details o f 
the unblinded safet y reviews, including the frequency and approximate timin g, are specified in 
the ISAC charter.
The approximate timing, decisio n criteria, and statistical methods associated with each possible
modificati on to the ongoing study will be fully described in the SAP and ISAC Charter and 
finalized prior to the first st udy unblinding.   
9.6. Data Monitoring Committee (DMC)
This study  will not have a data m onitoring commi ttee.  Independent s afety assessment committee 
inform ation isin Sect ion 10.1.5 and the ISAC charter .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
4710. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) In ternati onal Ethical  Guidelines
Applicable Internat ional Council for Harmonizat ion (ICH) Good Clinical Practice (GCP) 
Guidelines , and
Applicable laws and regulations .
The protocol, protocol amendments, ICF, IB, and other relevant documents (e .g., advertisements) 
must be submitted to an IRB/IEC by  [CONTACT_90741]/IEC
before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requi rements, policies, and procedures established by  
[CONTACT_1201]/IEC
Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required by 
[CONTACT_1744]/IEC procedures , and
Provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21 CFR, ICH gui delines, the IRB/IEC, and all other applicable local regulations .
Invest igator sites are compensated for participat ion in the study as detailed in the clinical trial
agreem ent.
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Invest igators are 
responsible for providing informat ion on financial interests during the study  and f or [ADDRESS_1078037] ions 
regarding the study .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
48Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Participants or thei r legally 
authori zed r epresentative will be required to sign a statement of informed consent that meets the 
requi rements of [ADDRESS_1078038] (HIPAA) requirements, where applicable, and the I RB/IEC or study  center.
Due to strict respi[INVESTIGATOR_41360], limited access to COVID -19 patient rooms and SARS -
CoV -2 transmissibilit y via droplet -contaminated paper, verbal consent and alternat ive methods 
of obtaining consent ( for exam ple, by [CONTACT_648]) will be allowed if approved by [CONTACT_1201]. 
If a signed paper copy  of the ICF is all owed by [CONTACT_2360] [INVESTIGATOR_41361], how i t will  be obtained and 
stored will need to be determined. Any variation from  the standard consent process due to 
isolation and infect ion control shoul d be sent to th e IRB for approval prior to enrollment.
The site should document the process in their regulatory  files and demo nstrate that the process 
has IRB concurrence or approval.
The m edical  record m ust include a statem ent that wri tten inform edconsent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. The 
authori zed person obtaining the informed consent and, if applicable, the individual designated to 
witness a verbal consent, must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally authorized 
representati veand is kept on file.
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_456]. Any part icipant records ,datasets
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be informed that theirpersonal study -related data will  be used by  [CONTACT_32855] h local data protecti on law. The l evel of disclosure m ust als o be 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent .
The parti cipant must be informed that theirmedical records m ay be examined by [CONTACT_32856] y Assurance auditors or ot her authorized personnel appo inted by  [CONTACT_456], by  
[CONTACT_6667]/IEC members, and by [CONTACT_32857].
The sponsor has processes in place to ensure data protection, informat ion securit y and data 
integrity.  These processes include appropri ate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.5. Committees Structure
The ISAC will consist of a chair external to Lilly  and will include at least two other Lilly  
physicians external to the PYAA study  team .  Th eISAC will be engaged in dosing decisio nsor 
if any of the stoppi[INVESTIGATOR_23893], and may also conduct periodic review sof available data to
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
49make reco mmendat ions on study  conduct. Details of the ISAC will be provided in the ISAC 
charte r.
10.1.6. Dissemination of Clinical Study Data
A clinical study  report will be provided for this study  and a summary  of study  information 
provi ded on publicly  available websi tes. 
10.1.7. Data Quality Assurance
Investigator responsibilities
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e .g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  [CONTACT_783888].
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provi de di rect a ccess to source data documents.
Data monitoring and management
The Monitoring Plan includes
monitoring details describing strategy , for example , risk-based init iatives in operations 
and qualit y such as risk management and mitigation strategi es and analyt ical risk-
based 
monitoring 
methods 
responsibilit ies 
requi rements 
handling of nonco mpliance issues ,and 
monitoring techniques.
The sponsor or designee is responsible for the data management of this study  includin g qualit y 
checking o f the data.   The sponsor assumes accountabilit y for acti ons del egated to other 
individuals (e .g., contract research organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered in the 
CRF by [CONTACT_783889], complete, and verifiable from source documents .  
They  will also ensure that the safet y and ri ghts of parti cipants are being protected ,and that the 
study  is being conducted in accordance wit h the currently approved protocol and any othe r study  
agreem ents, ICH GCP, and all applicable regu latory requirements.
Records retention and audits
Records and documents, including signed ICFs, pertaining to the conduct of this study  must be 
retained by [CONTACT_32862] (CTA)
unless local regulat ions or inst itutional policies requi re a l onger retenti on peri od. 
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
50No records may be destroy ed during the retention period without the written approval of the 
sponsor. No records may  be transferred to another locat ion or party  without wri tten notificat ion 
to the sponsor .
The s ponsor or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_90745], and by [CONTACT_90746].  Invest igators will be given notice 
before an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  [CONTACT_32864] -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  [CONTACT_11003] .
Data collected via the sponsor- provided data capture system swill be stored at third parties .The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.  Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention.  Data will subsequent ly be transferred fro m the central  vendor to the Sponsor data 
warehouse.
Data from co mplaint forms submitted to Sponsor will be encoded and stored in the global 
product compl aint management sy stem .
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF that are transcribed fro m source documents must be consistent with 
the source documents or the discrepancies must be explained. The invest igator may need to 
request previous medical records or transfer records, depending on the study . Current medical 
records m ustbe available.
The definit ion of what constitutes source data can be found in Sect ion 10.1.7 .
10.1.9. Study and Site Start and Closure
The study  start date i s the date on which the clinical study  will be open for recruit ment of 
participants.
Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will be cl osed upon study  
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
51completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at an y time, provi ded there i s reasonable cause 
and enough notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_17095]:
Failure of the invest igator to co mply with the protocol , the requi rements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  [CONTACT_17062] , or
Discontinuati on of  further study  intervent ion developm ent.
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as spec ified by [CONTACT_17096]. The invest igator shall prompt ly inform  the participant sand assure 
appropriate participant therapy  and/or foll ow-up.
10.1.10. Publication Policy
In accordance with the sponsor’s publication po licy, the results of th is study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
10.1.11. Investigator Information
Physicians with a specialt y in infect ious di sease, crit ical care, or pulmo nary disease may
participate as invest igators.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
5210.1.12. Long -Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of  the 
intervent ion or after  the intervent ion beco mes commercially  available.
This table describes the retention period for potential sample t ypes.
Sample Type Custodian Retention Period After Last Pa rticipa nt Visit
Pharmacogenetics sample Sponsor or designee up to 7years
Explo ratory  Biomarker Samples Sponsor or designee up to 7years
Pharmacokinetic (PK) sample Sponsor or designee up to 2 years
Pharmacodynamic Samples Sponsor or designee up to 7years
Immunogenicity (ADA) sample Sponsor or designee up to 7years
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
5310.2. Appendix 2: Clinical Laboratory Tests
Clinical laboratory  tests will be perform ed according to the SoA.  
Addit ional tests may be performed at any  time during the study  as determined necessary  by [CONTACT_447879].
Pregnancy testing will be performed according to the SoA.
Central  and l ocal laboratori es will be used.  The tablebelow describes when the local or central 
laboratory  will be used .
If the local laboratory  resul ts are used to m ake ei ther a study  interventi on decisi on or response 
evaluat ion, the results must be recorded i nthe CRF.
Laboratory  resul ts that coul d unblind the study  will not be reported to invest igative sites or other 
blinded personnel.
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in Sect ion [ADDRESS_1078039] ion 
8.2.4 .
Refer to Section 10.6 for recommended laboratory  testing for hypersensit ivity events.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
54Clinical Laboratory Tests Comments  
Hematology Assay ed by [CONTACT_783890] (RBCs -Red Blood Cells)
Mean cell volume 
Mean cell hemoglobin
Leukocytes (WBCs -White Blood Cells) 
Differential
   Neutrophils, segmented
   Lymphocy tes
   Monocytes
   Eosinophils
   Basophils
Platelets
Cell Morphology (RBC and WBC)
Clinical Chemistry Assay ed by [CONTACT_783891] 1 and if abnormal values occur
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT) Record on Day 1 and if abnormal values occur
Blood urea nitrogen (BUN)
Creatinine 
Creatine kinase (CK) Record o n Day [ADDRESS_1078040] on Day 1 and if abnormal values occur
Lactate dehydrogenase (LDH)
Calculations Completed locally
eGFR calculated by [CONTACT_9289] -EPI [INVESTIGATOR_783869]-Cov -2 viral infection determin ation Local laboratory
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
55Clinical Laboratory Tests Comments  
SARS-Cov -2Panel
C-Reactive Protein
Ferritin
D-dimer
Procalcitonin 
Troponin 
SARS -Cov-2 viral infection confirmation
Hormones (female) Assay ed by [CONTACT_12117].
Serum Pregnancy 
Urine Pregnancy
Pharmacokinetic (PK) Samples  Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
Pharmacodynamic Sample Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
   SARS -Cov -[ADDRESS_1078041]
Pharmacogenetics sample Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
Exploratory Biomarker Samples Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
Serum
   RNA (PAXGene)
Whole Blood (EDTA) 
   Whole Blood (EDTA) Epi[INVESTIGATOR_783870] -designated laboratory. 
Results will not be provided to the investigative sites.
   Anti-LY3819253 antibodies 
   Anti-LY3819253 antibodies neutralization
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
5610.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a clinical study  parti cipant tem porally 
associ ated wi th the use of study  intervent ion, whether or not considered related to the study  
intervent ion.
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory  finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of study  intervent ion.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or urinalysis) or 
other safet y assessments (e .g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the 
medical and scient ific judgment of the investigator (i .
e., not related to progression of 
underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomit ant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.
Events NOT Meeting the AE D efinition
Lack of drug effect i s not an AE in clinical studies, because the purpose of the clinical 
study  is to establish treatment effect.
The fo llowing s tudy-specific clinical events related to COVID -[ADDRESS_1078042] igator deems the eve nt to be rel ated to the administration of 
intervent ion:
oHypoxemia due to COVID -19 requiring supplemental oxygen;
oHypoxemia due to COVID -19 requiring non-invasive vent ilation or high flow 
oxygen devices;
oRespi[INVESTIGATOR_446387] -19 requiring invasiv e mechanical  vent ilation 
or ECMO
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
57Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying disease under study , unless 
judged by  [CONTACT_783892] r the participant’s 
condi tion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure , such as endoscopy orappendectomy . The condit ion 
that leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -exist ing disease (s) or condi tion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
Please note:  If an event is not an AE per definit ion above, then it cannot be an SAE.
AnSAE is defined as any AEthat:
a.Results in death
b.Is immediately life-threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were m ore severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
In general, hospi[INVESTIGATOR_783871] >”23 hour observat ion”and/or treatm ent that woul d not have been appropriate in 
the physician’s office or outpatient setting. Complications that occur during 
hospi [INVESTIGATOR_99453]. If a com plicat ion prol ongs hospi [INVESTIGATOR_783872], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_3094]” 
occurred or was necessary, the AE should be considered serious.
Hospi[INVESTIGATOR_17048] a pre -existing condit ion that di d not worsen 
from baseline is not considered an AE.
d.Results i n persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, 
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
58and accidental trauma (e .g., sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disrupt ion.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_783873] m ay requi re medical or surgi cal intervent ion to prevent one of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
oExamples of such events include intensive treatment in an eme rgency  room  or 
at hom e for allergic bronchospasm, blood dyscrasias or convulsio ns that do not 
resul t in hospi [INVESTIGATOR_28689], or devel opment of drug dependency  or drug abuse .
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (e .g., hospi[INVESTIGATOR_1088], laboratory  reports, and di agnosti cs reports) 
related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF .
It is notacceptable for the invest igator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor or designee in lieu of co mpletion of the AE/SAE CRF page.
There m ay be instances when copi[INVESTIGATOR_695428] . In this case, all participant ident ifiers, except the participant number, will 
be redacted on the copi[INVESTIGATOR_244877] n to Sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical informat ion. Whenever possible, the diagnosis (not the individual 
signs/symptom s) will be documented as the AE/SAE .
Assessment of Intensity /Severity
The invest igator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it to one of the fo llowing categori es, which together with serious criteria 
on the AE CRF (“result s in death” and “life -threatening”), are aligned with the Divisio n of 
AIDS (D AIDS )Table fo r Grading the Severit y of Adult and Pedi atric Adverse Events, versio n 
2.1 (July 2017) .
Mild: Mild symptoms causing no or minimal interference with usual social and functional 
activit ies, with intervention not indicated .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
59Moderate: Moderate symptoms causing greater than minimal interference wit h usual 
social and f uncti onal activities, with intervention indicated .
Severe: Severe symptoms causing inabilit y to perform usual social and functional 
activit ies, with intervention or hospi[INVESTIGATOR_374].
An event is defined as ‘serious’ when it meets at least [ADDRESS_1078043] igator is obligated to assess the relationship between study i ntervent ion and each 
occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship cannot be rul ed out .  
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to study  interventi on administrati on will be 
considered and invest igated.
The invest igator will also consult the invest igator’s brochure and/or Product Informat ion, for 
marketed products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/ SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred, and the invest igator has minimal 
inform ation to include in the init ial report to Sponsor or designee . However, i t is very  
important that the invest igator always assess the causalit y for every  event before the init ial 
transmissio n of the SAE data to Sponsor or designee .
The invest igator may change theiropi[INVESTIGATOR_3078] n of causalit y after consi derat ion of follow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  reporting 
requi rements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by [CONTACT_226428]/or causalit y of the AE or SAE as fully as possible . This 
may include addit ional laboratory  tests or investigations, histopathological examinat ions, or 
consultation wit h other health care professio nals.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
60If a participant dies during participation in the study or during a recognized fo llow-up period,
the invest igator will provide the sponsor or desi gnee with a copy  of any post -mortem findings 
including histopathology . 
New or updated informat ion will be recorded in the originally co mpleted CRF.
The invest igator will submit any updated SAE data to Spon sor or designee within [ADDRESS_1078044] igator to complete and 
sign the SAE CRF pages wit hin the designated reporting t ime frames.
Contacts for SAE reporting can be found in site training documents .
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
6110.4. Appendix 4: Contracepti veGuidance and Collection of Pregnancy 
Information
Women
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, additional eval uation shoul d be considered.
Woman not of Childbearing Potential (WOCBP)
Women in the fo llowing categori es are not co nsidered WOCBP
1.Prem enarchal
2.Prem enopausal  female wi th either
a.Docum ented hysterectomy
b.Docum ented bilateral  salpi[INVESTIGATOR_1656] , or
c.Docum ented bilateral  oophorectomy .
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above, 
(e.g., Müller ian agenesis, androgen insensit ivity), investi gator di scret ion shoul d be applied to 
determining study  entry .
Note: Documentation can come fro m the site personnel’s :review of the participant’s medical 
records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female is defined as, women with:
a.12 m onths of amenorrhea for women >55, with no need for FSH
b.12 m onths of amenorrhea for women >40 y ears old wi th FSH ≥40 m IU/mL and 
no other m edical condit ion such as anorexia nervosa and not taking medicat ions 
during the amenorrhea (e.g. oral contraceptives, hormones, gonadotropin 
releasing hormone, ant i-estrogens, select ive estrogen receptor modulators 
[SERMs ], or chemotherap y that induced amenorrhea)
Participation in the Study
Women of child- bearing potenti al may part icipate in this study.
Women of child- bearing potenti al must test negative for pregnancy  prior to ini tiation of 
treatm ent as indicated by  a negative serum pregna ncy test at the screening visit.
Women of child- bearing potenti al who are completely  abstinent or in a same sex relat ionship ,as 
part of their preferred and usual lifest yle,must agree to either remain abst inent or stay  in a same 
sex rel ationship wit hout s exual relat ionships with males.
All other wom en of child- bearing potential must agree to use two forms of effective 
contraception, where at least one form is highly effective (less than 1% failure rate), for the 
entirety of the study . 
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
62Abstinence or con tracepti on m ust continue for [ADDRESS_1078045] ive method sof contracepti on (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives
implanted contracepti ves,or 
intrauterine devices . 
Effect ivemethod sof contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges .  
Not Acceptable Methods of Contraception
Use of m ale and female condoms as a double barrier meth od is not considered acceptable due to 
the high failure rate when these barrier methods are combined .
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not a n effect ive or 
acceptable method of contracepti on. 
Periodic abst inence (e.g ., cal endar, ovul ation, symptothermal, post -ovulation methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
Men
Men, regardl ess of their fertilit y status, m ust agree to ei ther remain abstinent (if this is their 
preferred and usual lifest yle) or use condoms as well as one addit ional highly effect ive method 
of contracepti on(less than 1% failure rate) or effective method of contraception with non-
pregnant women of child bearing po tential partners for the durati on of  the study  and until their 
plasma concentrations are below the level that could result in a relevant potential exposure to a 
possible fetus, predicted to be 90daysafter the l ast dose .
Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of est imated relevant potential exposure to the fetus , predi cted to be [ADDRESS_1078046] ive method sof contracepti on (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives
implanted con tracepti ves,or 
intrauterine devices . 
Effect ivemethod sof contraception comprise but are not limited to diaphragms wit h spermici de 
or cervi cal sponges .  
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
63Men and their partners may choose to use a double –barrier m ethod of contraception thatmust 
include use of a spermicide .
Other Guidance
Men should refrain fro m sperm  donat ion for the durati on of  the study  and unt il their plasma 
concentrations are below the level that could result  in a relevant potenti al exposure to a possible 
fetus , predi cted to be [ADDRESS_1078047] pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only to 
male participants who receive study  intervent ion.
After obtaining the necessary  signed informed consent from the pregnant female partner direct ly, 
the invest igator will record pregnancy informat ion on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partner’s pregnancy. 
The female partner will also be followed to determine the outcome of the pregnancy . 
Inform ation on the status of the mother and child will be forwarded to the sponsor. Generally, 
the follow-up will be no l onger than 6 to 8 weeks following the estimated delivery date. Any 
termination o f the pregnancy  will be reported including fetal status (presence or absence of 
anomalies) andindication for the procedure. 
Female Participants who become pregnant
The invest igator will co llect pregnancy  information on any female participant who becomes 
pregnant while part icipating in this study .  The init ial information will  be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning o f a participant's 
pregnanc y. 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. Generally, fo llow-up will not be r equired for longer than [ADDRESS_1078048] imated delivery date. Any terminat ion of pregnancy will be reported, including 
fetal status (presence or absence of ano malies) or indicat ion for the procedure.
While pregnancy  itself is not considered to b e an AE or SAE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <2 0 weeks gestational age) or still birth (occurring at >20
weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any post -study pregnancy related SAE considered reasonably related to the study intervention 
by [CONTACT_41444] 8.3.4 . While the 
investigator is not obligated to actively seek this informat ion in former study  parti cipants, he or 
she m ay learn of an SAE through spontaneous reporting.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
64Any female part icipant who becomes pregnant while participat ing in the study  will be withdrawn 
from the study  and will  follow the standard discontinuat ion process.   
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
6510.5. Appendix 5: Genetics
Sample collect ion informat ion is found in Appendix 2, Section 10.2 (Clinical Laboratory Tests).
Genet ic variat ion may impact a participant’s response to study  intervent ion, suscept ibilit y to, and 
severit y and pr ogressi on of  disease. Vari able response to study  intervent ion may be due to 
genet ic determinants that impact drug absorption, distribut ion, metabo lism, and excretion; 
mechanism o f action of  the drug; di sease et iology; and/or m olecular subt ype of the diseas e being 
treated. Therefore, where local regulat ions and IRB/IEC allow, a blood sample will be collected 
for DNA analysis fro m consenting part icipants.
DNA samples may be used for research related to SARS -CoV -2and related diseases. They may 
also be used to develop tests/assays including diagnostic tests related to LY3819253 orSARS -
CoV -2. Genetic research may consist of the analysis of one or more candidate genes or the 
analysis of genet ic markers throughout t he geno me as appropriate.
The samples may  be analyzed as part of a mult i
-study  assessment of genetic factors involved in 
the response to LY3819253 or study intervent ions of this class to understand study  disease or 
related condi tions.
The results of genet ic analyses m ay be reported in the clinical study  report (CSR) or in a separate 
study  summary .
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
The samples will be retained at a facilit y selected by  [CONTACT_3210] i ts designee while research 
on SARS -CoV -2continues but no l onger than 7years or other period as per local requirements.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
6610.6. Appendix 6: Recommended Laboratory Testing for Hypersensitivity 
Events.
Laboratory  assessment s should be performed if the participant experiences generalized urticaria 
or if anaphylaxis is suspected .
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the 
event; however, samples may be obtained as late as [ADDRESS_1078049] the time at which the sample 
was collected.
Obtain a fo llow-up sam ple after approximately  4 weeks.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
67Clinical Lab Tests for Hypersensitivity Events
Hypersensitivity Tests Notes
Selected test may be obtained in the event of anaphylaxis or 
systemic allergic/hypersensitivity reactions.
LY3819253 anti-drug 
antibodies 
(immunogenicity/ADA)Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigativ e sites.
LY3819253 concentrations 
(PK)Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
Tryptase Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
Urine N- methylhistamine testing is performed in addition to 
tryptase testing. Collect the first void urine following the event. 
Collect a follow -up urine sampleafter approximately 4 weeks .
Note: If a tryptase sample is obtained more than 2 hours after the
event (that is, within 2 to 12 hours), or is not obtained because more 
than [ADDRESS_1078050] Will be performed if a validated assay is available.
Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
NOTE: The basophil activation test is an in vitro cell based assay 
that only requires a serum sample. It is a surrogate assay fo r drug 
specific IgE but is not specific for IgE.
Complement (C3, C3a and 
C5a)Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
Cytokine panel Assayed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the investigative sites.
Abbreviations: IgE = immunoglobulin E; PK = pharmacokinetic.
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
6810.7. Appendix 7:  Nasopharyngeal Swab Instructions
Personal Protective Equipment for healthcare provider collecting specimen: 
•N95 or hi gher-level respi[INVESTIGATOR_13521] (or facemask if a respi[INVESTIGATOR_783874]), ey e 
protecti on, gl oves, and a gown.
Nasopharyngeal swab: 
•Use only synt hetic fiber swabs with plastic or wire shafts. 
•Have pa rticipant blow nose to clear.  Provide t issues for pa rticipant in case of sneeze.
•Insert minit ip swab with a flexible shaft (wire or plastic) through the nostril parallel to the 
palate (not upwards) until resistance is encountered or the distance is equivalent to that 
from the ear to the nostril o f the participa nt, indicating contact [CONTACT_783893]. 
•Swab shoul d reach depth equal  to di stance from nostrils to outer opening o f the ear. 
•Gent ly rub and roll the swab. Leave swab in place for several seconds to absorb 
secretions. 
•Slowly  remove swab while rotating it. 
•Repeat in other nostril using same swab unless there is an obstruction from a deviated 
septum or other blockage. 
•Swabs should be placed immediately into a sterile transport tube containing 2 -3mL of 
viral transport medium and stored at 2 -8°C for up to 72 hours, then at -70°C or below.

CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
6910.8. Appendix 8: FDA Guidance for Industry -Baseline Severity 
Categorization for COVID -19.
This appendix contains pages fro m the COVID -19: Developi[INVESTIGATOR_783875] U.S. Department of Healt h and 
Hum an Services, FDA, Center for Drug Evaluation and Research (CDER), and Center for 
Biologics Evaluat ion and Research (CBER), dated May 2020 (FDA resource page, [WWW]) .

CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
70

CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
7110.9. Appendix 9: Abbreviations and Definitions
Term Definition
ADA anti-drug antibody
ADE antibody -dependent enhancement
blinding A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.
CIOMS Council forInternational Organizations ofMedical Sciences
complaint A complaint is any wri tten, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, glo bal safety physician or other medical officer.
ECG electrocardiogram
EDC electronic data capture system
enroll The act of assigning a participant to a treatment.  Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
GCP good clinical practice
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
Informed consent A process by [CONTACT_9444] a participant voluntarily confirms his or her willingness to 
participate in a particular study , after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate.  Informed consent is 
documented by [CONTACT_3553] a written, signed and dated informed consent form .
intervention A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IWRS interactive web -response sy stem
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
72NIAID Natio nal Institute of Allergy and Infectious Diseases
NIH Natio nal Institutes of Health
NEWS2 Natio nal Early  Warning Score
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control
PK/PD pharmacokinetics/pharmacodynamics
SAE serious adver se event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
WHO World Health Organization
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
7310.10. Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment (a): 01 June 2020
Overall Rationale for Amendment (a):
This amendment addresses the [LOCATION_002] Food and Drug Administrati on (FDA) feedback.  
Addit ional changes were made to address newly available internal or external informat ion.  
Other changes were made for clarit y and consistency .  This tabl e describes the changes made for 
Amendment (a)
Section # and Nam e Description of Change Brief Rationale
Title Page Changed PI[INVESTIGATOR_783876] 3. 
Synopsis Updates to general sequence of 
events during double -blind 
treatment and assessment periodTo more accurately represent the sequence
Synopsis Updated Number of Participants 
and Intervention Groups and 
Duration sections.Based on new internal and external information
Synopsis Updated when the independent 
safety assessment comm ittee will 
be engagedPer FDA feedback
Schema Updates to cohort [ADDRESS_1078051] a nd removed indicator for 
sentinel dosing for Cohort 4. 
1.3 Schedule of 
ActivitiesScreening visit window update Correction to align with randomization and dosing
1.3 Schedule of 
ActivitiesVital Signs -updated 
comments/instructionsPer FDA feedback
1.3 Schedule of 
ActivitiesClinical symptoms -updated 
comments/instructionsFor clarity
1.3 Schedule of 
ActivitiesPharmacokinetic (PK), 
pharmacodynamic (PD), 
immunogenicity and exploratory 
biomarker samples –updated 
comments/instructionsFor clarity
3Objectives and 
EndpointsSecondary PK objective 
endpoint changedMore clinically meaningful
3 Objectives and 
EndpointsSecondary PD objective 
endpointAdded timepoints for analysis
3 Objectives and 
EndpointsMoved PD secondary endpoint 
to exploratoryDecision that viral clearance should be exploratory
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
74Section # and Nam e Description of Change Brief Rationale
3 Objectives and 
EndpointsAdded 2 exploratory objectives Per FDA feedback
4.1. Overall Design Updates to general sequence of 
events during double -blind 
treatment and assessment periodTo more accuratel y represent the sequence
4.1.1. Single -ascending 
Dose DesignUpdated text for the change with 
Cohort 4Cohort 4 increase in sample size
4.2. Scientific Rationale 
for Study DesignAdded text for Cohort 4 Cohort 4 increase in sample size
4.2. Scientific Rationale 
for Study DesignUpdated text for participant 
populatio nThe I/E criteria were updated to provide more 
clarity ,and the severity of illness definitions were 
changed to the FDA definitions.
4.3. Justification for 
DoseUpdated projected half -life and 
in vitro IC90New data available for the updates
5.1 Inclusion Criteria Increased age limit to 85 years Based on clinical site feedback
5.1 Inclusion Criteria Updated disease characteristics In order to provide more clarity based on clinical 
site feedback .  Severity  definitions were updated 
to those provided by [CONTACT_1622].
5.1 Inclusion Criteria Rem oved criterion describing 
symptomsNot needed because of the update to the disease 
characteristics
5.1 Inclusion Criteria Updated criterion for 
hospi[INVESTIGATOR_783877]
5.1 Inclusion Criteria Criterio n #6 was merged with 
Criterio n 5Correction 
5.2. Exclusion Criteria Updated criterion for mechanical 
ventilatio n to state, “invasive 
mechanical ventilation”For clarity
5.2. Exclusion Criteria The timing of SpO2 
measurement w hile breathing 
room air was changed to occur at 
screeningSpO2 is measured at screening and instructions 
were added for participants on supplemental 
oxygen.
5.2. Exclusion Criteria Rem oved respi[INVESTIGATOR_783878]
6.1. Study 
Intervention(s) 
AdministeredAdded information about Cohort 
4.Instructio ns for infusion volume and rate will be in 
the pha rmacy  instructio ns.
6.1. Study 
Intervention(s) 
AdministeredUpdated the monitoring 
instructio nsPer FDA feedback
[IP_ADDRESS]. Management of 
Infusion ReactionsRem oved table of specific 
guidelines Investigators should determine the severity of the 
infusion reaction and manage the reactions based 
on standard of care and their clinical judgment.
6.5. Co ncomitant 
TherapyUpdated text about standard of 
care and allowing remdesivir 
during the studyPer FDA feedback
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
75Section # and Nam e Description of Change Brief Rationale
6.6.1. Dose escalation 
criteriaUpdated when the independent 
safety assessment committee 
(ISAC) would be engaged for 
reviewsPer FDA feedback
6.6.2. Temporary 
Stoppi[INVESTIGATOR_783879] 6.6.1.
8.2.4. Clinical 
Laborato ry 
AssessmentsUpdated required text Per L illy required language
8.3.5. Pregnancy Updated collection timing to 90 
daysNew data available for the update
8.3.7. Infusion -related 
ReactionsUpdated table Rem oved link to table that was removed in Section 
[IP_ADDRESS].
8.9. Immunogenicity Rem oved “ predose” Refer to SoA for sample times
8.6. Pharmacodynamics Updated text to clarify how the 
samples may be usedPer FDA feedback
9.2. Sample Size 
DeterminationUpdated sample size information Based on new internal and external information
9.2. Sample Size 
DeterminationCorrected Bayesian critical 
success factor equationcorrection
9.4.1. General 
ConsiderationsUpdated table corrections
9.4.1. General 
Considerationsupdated one sentence and 
removed anothercorrections
9.4.2. Safety analyses Rem oved listings Parameters will not be listed, only summarized
9.4.4. Exploratory 
EndpointsAddition of exploratory endpoint Per Section 3. Objectives and Endpoints
9.4.3. Pharmacokinetic 
and Pharmacodynamic 
Analy sesUpdated PK and PD analy ses To match endpoint sin Section 3.
9.4.4. Exploratory 
EndpointsUpdated exploratory endpoints To match table in Section 3.
10.1.5. Committees 
StructureUpdated when the Independent 
Safety Assessment Committee 
(ISAC )will be engagedPer FDA feedback
10.1.12. Long -term 
sample RetentionUpdated sample retention times Per internal Lilly decision
10.2. Appendix 2: 
Clinical Laboratory 
TestsUpdates to text For clarity
10.4. Appendix 4: 
Contraceptive Guidance 
and Collection of 
Pregnancy InformationUpdated collection timing to 90 
daysNew data available for the update
10.5. Appendix 5: 
GeneticsUpdated sample retention time Per internal Lilly decision
10.8. Appendix 8 Added an appendix to contain 
FDA resource pageThe COVID -19 severity criteria from this resource 
page will be used for inclusion criteria purposes
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
76Section # and Nam e Description of Change Brief Rationale
Section 11 References Added FDA reference For inclusion criteria
Throughout the 
protocolMinor editorial and formatting 
changesMinor, therefore not described
CONFIDENTIAL Protocol  number J2W -MC-PYAA (b)
7711. References
Divisio n of AIDS ( DAIDS )Table for Grading the Severit y of Adult and Pediatric Adverse 
Events . Nati onal Inst itute of Allergy and Infect ious Di seases .National Insti tutes of Heal th. US 
Departm ent of Healt h and Human Services. Corrected version 2.1 .July 2017 . Available at: 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf . Accessed: [ADDRESS_1078052] iveness o f convalescent plasma therapy  in severe COVID -19 pati ents. 
PNAS . 2020. Available at: https://doi.org/10.1073/pnas.[PHONE_5957].
FDA resource page. COVID -19: Developi[INVESTIGATOR_446392] . Food and Drug Administration web site. Available at: 
https://www.fda.gov/regulatory -inform ation/search -fda-guidance -docum ents/covid -
19-
developi[INVESTIGATOR_007] -drugs -and-biological -products -treatm ent-
or-prevent ion. Accessed 26 May 2020.
Hoffmann M, Kleine -Weber H, Schroeder S, Krüger N, Herrier T, Erichsen S, Schiergens TS, 
Herrler G, Wu NH, Nitsche A, M üller M, Drosten C, P öhlmann, S. SARS -Cov-2 Cell Entry  
Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. 
Cell. 2020;181:1
-10. DOI: 10.1016/j.cell.2020.02.052 .
Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, Yu L. Clinical features and progression of acute 
respi [INVESTIGATOR_446393] 2019. medRxiv. Posted 27 February
2020. preprint DOI : https://doi.org/10.1101/2020.02.17.[ADDRESS_1078053] itutes for Health (NIH) resource page . Management of Persons with COVID -19.  
NIH web site. Available at :
https://covid19treatmentguidelines.nih.gov/overview/management -of-covid-19/ . Accessed : [ADDRESS_1078054] asma. JAMA. Published online 27March 2020. DOI:10.1001/jama.2020.4783 .